Blood Reviews
Volume 24, Issue 4 , Pages 143-150 , July 2010

Immune hemolytic anemia associated with drug therapy

References 

  1. Snapper I, Marks D, Schwartz L, Hollander L. Hemolytic anemia secondary to Mesantoin. Ann Intern Med. 1953;39:619–623
  2. Harris JW. Studies on the mechanism of a drug-induced hemolytic anemia. J Lab Clin Med. 1956;47:760–775
  3. Dausset J, Contu L. Drug-induced haemolysis. Ann Rev Med. 1967;18:55–70
  4. Worlledge SM. Immune drug-induced haemolytic anaemias. Semin Hematol. 1969;6:181–200
  5. Petz LD, Garratty G. Acquired immune hemolytic anemias. New York: Churchill Livingstone; 1980;
  6. Garratty G. Current viewpoints on mechanisms causing drug-induced immune hemolytic anemia and/or positive direct antiglobulin tests. Immunohematology. 1989;5:97–106
  7. Garratty G, Arndt PA. An update on drug-induced immune hemolytic anemia. Immunohematology. 2007;23:105–119
  8. Hine LK, Gertsman BB, Wise RP, Tsong Y. Mortality resulting from blood dyscrasias in the United States, 1984. Am J Med. 1990;88:151–153
  9. Andersohn F, Bronder E, Klimpel A, Garbe E. Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin case-control surveillance study. Am J Hematol. 2004;77:316–318
  10. Kaufman DW, Kelly JP, Johannes CB, Sandler A, Harmon D, Stolley PD, et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood. 1993;82:14–18
  11. van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf. 2004;27:1243–1252
  12. Andrés E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008;15:15–21
  13. Petz LD, Garratty G. Immune hemolytic anemias. 2nd ed.. Philadelphia: Churchill Livingstone; 2004;
  14. Klein NP, Ray P, Carpenter D, Hansen J, Lewis E, Fireman B, et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine. 2010;28:1062–1068
  15. Landsteiner K, van der Scheer J. On cross reactions of immune sera to azoproteins. II. Antigens with azocomponents containing two determinant groups. J Exp Med. 1938;67:709–723
  16. Eisen HH, Orris L, Belman S. Elicitation of delayed allergic skin reactions with haptens; the dependence of elicitation on hapten combination with protein. J Exp Med. 1952;95:473–487
  17. Eisen HN, Carsten ME, Belman S. Studies of hypersensitivity to low molecular weight substances. III. The 2, 4-dinitrophenyl group as a determinant in the precipitin reaction. J Immunol. 1954;73:296–308
  18. Salama A, Mueller-Eckhardt C, Kissel K, Pralle H, Seeger W. Ex vivo antigen preparation for the serological detection of drug-dependent antibodies in immune haemolytic anaemias. Br J Haematol. 1984;58:525–531
  19. Salama A, Mueller-Eckhardt C. The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. N Engl J Med. 1985;313:469–474
  20. Ackroyd JF. The immunological basis of purpura due to drug hypersensitivity. Proc R Soc Med. 1962;55:30–36
  21. Miescher PA, Miescher A. Die sedormid-anaphylaxie. Schweiz Med Wochenschr. 1952;82:1279–1282
  22. Miescher PA, Gorstein F. Mechanisms of immunogenic platelet damage. In:  Johnson SA,  Monto RW,  Rebuck JW,  Horn RC editor. Blood platelets. London: Churchill; 1961;p. 671
  23. Miescher PA, Pepper JJ. Drug-induced immunologic blood dyscrasias. In:  Meischer PA,  Müeller-Eberhard HJ editor. Textbook of immunopathology. 2nd ed. Philadelphia: WB Saunders; 1976;p. 421–432
  24. Shulman NR. Immunoreactions involving platelets. I. A steric and kinetic model for formation of complex from a human antibody, quinidine as a haptene, and platelets; and for fixation of complement by the complex. J Exp Med. 1958;107:665–690
  25. Shulman NR, Rall JE. Mechanism of blood cell destruction in individuals sensitized to foreign antigens. Trans Assoc Am Physicians. 1963;76:72–83
  26. Shulman NR. A mechanism of cell destruction in individuals sensitized to foreign antigens and its implications in autoimmunity. Ann Int Med. 1964;60:506–521
  27. Croft JD, Swisher SN, Gilliland BC, Bakemeier RF, Leddy JP, Weed RI. Coombs'-test positivity induced by drugs. Mechanisms of immunologic reactions and red cell destruction. Annals Int Med. 1968;68:176–187
  28. Garratty G, Petz LD. Drug-induced immune hemolytic anemia. Am J Med. 1975;58:398–407
  29. Ley AB, Harris JP, Brinkley M, Liles B, Jack JA, Cahan A. Circulating antibodies directed against penicillin. Science. 1958;127:1118–1119
  30. Garratty G. Immune cytopenia associated with antibiotics. Trans Med Rev. 1993;VII:255–267
  31. Carstairs KC, Breckenridge A, Dollery CT, Worlledge SM. Incidence of a positive direct Coombs test in patients on α-methyldopa. Lancet. 1966;2:133–135
  32. Worlledge SM, Carstairs KC, Dacie JV. Autoimmune haemolytic anaemia associated with alpha-methyldopa therapy. Lancet. 1966;2:135–139
  33. Spath P, Garratty G, Petz L. Studies on the immune response to penicillin and cephalothin in humans. II. Immunohematologic reactions to cephalothin administration. J Immunol. 1971;107:860–869
  34. Ackroyd JF. Immunological mechanisms in drug hypersensitivity. In:  Gell PCH,  Coombs RRA,  Lachmann PJ editor. Clinical aspects of immunology. 3rd ed. Oxford: Blackwell Scientific; 1975;p. 913
  35. Cronin AE. The immunology of allergic drug reactions. Doctoral thesis. Cambridge, MA: University of Cambridge, 1965.
  36. Christie DJ, Mullen PC, Aster RH. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest. 1985;75:310–314
  37. Smith ME, Reid DM, Jones CE, Jordan JV, Kautz CA, Shulman NR. Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent. J Clin Invest. 1987;79:912–917
  38. Jordan JV, Smith ME, Reid DM, Jones CE, Kautz CA, Shulman NR, et al. A tolmetin-dependent antibody causing severe intravascular hemolysis binds to erythrocyte band 3 and requires only the F(ab)2 domain to react. Blood. 1985;66(S):104a;abstr
  39. Habibi B. Drug induced red cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias. Br J Haematol. 1985;61:139–143
  40. Mueller-Eckhardt C, Salama A. Drug-induced immune cytopenias: a unifying pathogenetic concept with special emphasis on the role of drug metabolites. Transfus Med Rev. 1990;IV:69–77
  41. Landsteiner K. In: The specificity of serological reactions. Rev. ed. Cambridge, MA: Harvard University Press; 1947;p. 185
  42. Kitagawa M, Yagi Y, Pressman D. The heterogeneity of combining sites of antibodies as determined by specific immunoadsorbents. II. Comparison of elution patterns obtained with anti-p-azobenzoate antibodies by different kinds of immunoadsorbent and eluting hapten. J Immunol. 1965;95:455–465
  43. Allison AC, Denman AM, Barnes RD. Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity. Lancet. 1971;298:135–140
  44. Gottlieb AJ, Wurzel HA. Protein-quinone interaction: in vitro induction of indirect antiglobulin reactions with methyldopa. Blood. 1974;43:85–97
  45. LoBuglio AF, Jandl JH. The nature of the alphamethyldopa red-cell antibody. N Engl J Med. 1967;276:658–665
  46. Dameshek W. Alpha-methyldopa red-cell antibody: cross-reaction or forbidden clones. N Engl J Med. 1967;276:1382
  47. Kirtland HH, Mohler DN, Horwitz DA. Methyldopa inhibition of suppressor-lymphocyte function. N Eng J Med. 1980;302:825–832
  48. Garratty G, Arndt P, Prince HE, Shulman IA. The effect of methyldopa and procainamide on suppressor cell activity in relation to red cell autoantibody production. Br J Haematol. 1993;84:310–315
  49. Garratty G, Arndt PA. Positive direct antiglobulin tests and haemolytic anaemia following therapy with beta-lactamase inhibitor containing drugs may be associated with nonimmunologic adsorption of protein onto red blood cells. Br J Haematol. 1998;100:777–783
  50. Broadberry RE, Farren TW, Bevin SV, Kohler JA, Yates S, Skidmore I, et al. Tazobactam-induced haemolytic anaemia, possibly caused by non-immunological adsorption of IgG onto patient's red cells. Transfus Med. 2004;14:53–57
  51. Arndt PA, Leger RM, Garratty G. Positive direct antiglobulin tests and haemolytic anaemia following therapy with the beta-lactamase inhibitor, tazobactam, may also be associated with non-immunologic adsorption of protein onto red blood cells (letter). Vox Sang. 2003;85:53
  52. Arndt P, Garratty G, Isaak E, Bolger M, Lu Q. Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug-induced nonimmunologic protein adsorption. Transfusion. 2009;49:711–718
  53. Arndt P, Garratty G. Is severe immune hemolytic anemia, following a single dose of cefotetan, associated with the presence of “naturally-occurring” anti-cefotetan?. Transfusion. 2001;41:24S;abstr
  54. Arndt PA, Leger RM, Garratty G. Serology of antibodies to second- and third-generation cephalosporins associated with immune hemolytic anemia and/or positive direct antiglobulin tests. Transfusion. 1999;39:1239–1246
  55. Anderson AD, Nelson JM, Rossiter S, Angulo FJ. Public health consequences of use of antimicrobial agents in food animals in the United States. Microb Drug Resist. 2003;9:373–379
  56. Shea KM. Nontherapeutic use of antimicrobial agents in animal agriculture: implications for pediatrics. Pediatrics. 2004;114:862–868
  57. Salama A. Drug-induced immune hemolytic anemia. Expert Opin Drug Saf. 2009;8:73–79
  58. Garratty G. Drug-induced immune hemolytic anemia. Hematology. Am Soc Hematol Educ Program. 2009;73–79
  59. Davenport RD, Judd WJ, Dake LR. Persistence of cefotetan on red blood cells. Transfusion. 2004;44:849–852
  60. Doratota S, Recht M, Garratty G, Krupicka M, Thomas GA, Boshkov L. Successful treatment of life-threatening ceftriaxone-induced hemolysis by plasmapheresis. Transfusion. 2009;49(S):13A;abstr
  61. Arndt PA, Garratty G. Cross-reactivity of cefotetan and ceftiaxone antibodies, associated with hemolytic anemia, with other cephalosporins and penicillin. Am J Clin Pathol. 2002;118:256–262
  62. Viraraghavan R, Chakravarty AG, Soreth J. Cefotetan-induced haemolytic anaemia. A review of 85 cases. Adv Drug React Toxicol Rev. 2002;21:101–107
  63. Garratty G, Leger RM, Arndt PA. Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures. Am J Obstet Gynecol. 1999;181:103–104
  64. Arndt PA. Practical aspects of investigating drug-induced immune hemolytic anemia due to cefotetan or ceftriaxone – a case study approach. Immunohematology. 2002;18:27–32
  65. Quillen K, Lane C, Hu E, Pelton S, Bateman S. Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection. Pediatr Infect Dis J. 2008;27:357–358
  66. Leger RM, Arndt PA, Garratty G. Serological studies of piperacillin antibodies. Transfusion. 2008;48:2429–2434
  67. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33:230–239
  68. Di Raimondo F, Giustolisi R, Cacciola E, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma. 1993;11:63–68
  69. Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolyitc anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol. 1995;91:341–344
  70. Gonzalez H, Leblond V, Azar N, et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther. 1998;40:113–118
  71. Hamblin TJ, Orchard JA, Myint H, Oscier DG. Fludarabine and hemolytic anemia in chronic lymphocytic leukemia. J Clin Oncol. 1998;16:3209–3210
  72. Dearden C, Wade R, Else M, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008;111:1820–1826
  73. Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol. 1998;16:1885–1889
  74. Petz LD. Immunohematologic problems associated with bone marrow transplantation. Transfus Med Rev. 1987;1:85–100
  75. Wong W, Merker JD, Nguyen C, Berquist W, Jeng M, Viele M, et al. Cold agglutinin syndrome in pediatric liver transplant recipients. Pediatr Trnasplantation. 2007;11:931–936
  76. Kitamura T, Mizuta K, Kawarasaki H, Sugawara Y, Makuuchi M. Severe hemolytic anemia related to production of cold agglutinins following living donor liver transplantation: a case report. Transplant Proc. 2003;35:399–400
  77. DiGuiseppe JA, Bastacky SI, Shirey RS, Silberman MA, Hutchins GM, Ness PM. Tacrolimus-related posttransplant lymphoproliferative disorder presenting as autoimmune hemolytic anemia. Arch Pathol Lab Med. 1996;120:282–285
  78. Elimelakh M, Dayton V, Park KS, Gruessner AC, Sutherland D, Howe RB, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica. 2007;92:1029–1036

PII: S0268-960X(10)00027-5

doi: 10.1016/j.blre.2010.06.004

Blood Reviews
Volume 24, Issue 4 , Pages 143-150 , July 2010

Article Tools

* Image Usage & Resolution